BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33990379)

  • 1. Targeting monoamine oxidase A for T cell-based cancer immunotherapy.
    Wang X; Li B; Kim YJ; Wang YC; Li Z; Yu J; Zeng S; Ma X; Choi IY; Di Biase S; Smith DJ; Zhou Y; Li YR; Ma F; Huang J; Clarke N; To A; Gong L; Pham AT; Moon H; Pellegrini M; Yang L
    Sci Immunol; 2021 May; 6(59):. PubMed ID: 33990379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
    Wang YC; Wang X; Yu J; Ma F; Li Z; Zhou Y; Zeng S; Ma X; Li YR; Neal A; Huang J; To A; Clarke N; Memarzadeh S; Pellegrini M; Yang L
    Nat Commun; 2021 Jun; 12(1):3530. PubMed ID: 34112755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression.
    Lapierre JA; Geary LA; Jang JK; Epstein AL; Hong F; Shih JC
    Biochem Biophys Res Commun; 2022 Dec; 634():100-107. PubMed ID: 36242915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
    Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC
    BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Type A monoamine oxidase and serotonin are coordinately involved in depressive disorders: from neurotransmitter imbalance to impaired neurogenesis.
    Naoi M; Maruyama W; Shamoto-Nagai M
    J Neural Transm (Vienna); 2018 Jan; 125(1):53-66. PubMed ID: 28293733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting monoamine oxidase A: a strategy for inhibiting tumor growth with both immune checkpoint inhibitors and immune modulators.
    Ma Y; Chen H; Li H; Zhao Z; An Q; Shi C
    Cancer Immunol Immunother; 2024 Feb; 73(3):48. PubMed ID: 38349393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy.
    Han H; Li H; Ma Y; Zhao Z; An Q; Zhao J; Shi C
    Cancer Lett; 2023 Jun; 563():216188. PubMed ID: 37076041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer.
    Yang XG; Li YY; Zhao DX; Cui W; Li H; Li XY; Li YX; Wang D
    Oncol Rep; 2021 Mar; 45(3):1306-1314. PubMed ID: 33650669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of [3H]quinpirole binding at striatal D2 dopamine receptors by a monoamine oxidaseA-like site: evidence from radioligand binding studies and D2 receptor- and MAO(A)-deficient mice.
    Levant B; Morgan KA; Ahlgren-Beckendorf JA; Grandy DK; Chen K; Shih JC; Seif I
    Life Sci; 2001 Nov; 70(2):229-41. PubMed ID: 11787947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
    Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD96 Is an Immune Checkpoint That Regulates CD8
    Mittal D; Lepletier A; Madore J; Aguilera AR; Stannard K; Blake SJ; Whitehall VLJ; Liu C; Bettington ML; Takeda K; Long GV; Scolyer RA; Lan R; Siemers N; Korman A; Teng MWL; Johnston RJ; Dougall WC; Smyth MJ
    Cancer Immunol Res; 2019 Apr; 7(4):559-571. PubMed ID: 30894377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-isoniazid conjugate regulates immune response and tumor microenvironment to enhance cancer therapy.
    Jin C; Li J; Yang X; Zhou S; Li C; Yu J; Wang Z; Wang D; He Z; Jiang Y; Wang Y
    Int J Pharm; 2023 Jan; 631():122509. PubMed ID: 36549403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
    Miao G; Sun X
    Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.